IR-News

AUSSENDER



Biofrontera AG
Ansprechpartner: Investor & public relations
Tel.: +49 (0) 214 87 63 20
E-Mail: press@biofrontera.com
pta20171120030
Business news for the stock market

Biofrontera AG: Biofrontera Announces Conference Call to Discuss Third Quarter 2017 Financial Results

Leverkusen (pta/20.11.2017/16:00 UTC+1) Biofrontera AG (ISIN: DE0006046113), the specialist for the treatment of sun-induced skin cancer, will be announcing its financial results for the 9 month period ended September 30, 2017 on 27 November 2017.

Conference calls for shareholders and interested investors will be held on 27 November 2017 at the following times:

10.00am CET (4.00am EDT) conference call in German:
Dial-in number: +49-(0)69 271340800
Conference code: 57010235#

2.00pm CET (8.00am EDT) conference call in English:
Dial-in number Germany: +49-(0)69 271340801
Dial-in number UK: +44 203 36 45 807
Dial-in number USA: +1 240 64 50 345
Dial-in number USA (New York): +1 646 66 37 901
Conference code: 74490603#

Enquiries, please contact:

Biofrontera AG
Thomas Schaffer, Chief Financial Officer
+49 (0) 214 87 63 2 0
press@biofrontera.com

IR Germany: Brainwell Asset Solutions
Jürgen Benker
+49 (0) 152 08931514

IR UK: Seton Services
Toni Vallen
+44(0) 20 7729 0805

IR and PR US: The Ruth Group
IR: Tram Bui
+1 646-536-7035
PR: Kirsten Thomas
+1 508-280-6592

About Biofrontera:
Biofrontera AG is a biopharmaceutical company specializing in the development, sale and distribution of dermatological drugs and medical cosmetics. The Leverkusen, Germany-based company, which has approximately 130 employees worldwide, develops and distributes innovative products for the care, protection and treatment of the skin. Biofrontera's combination lead product is topical prescription drug Ameluz® and medical device BF-RhodoLED® for the photodynamic therapy (PDT) treatment of superficial skin cancer and its precursors. Ameluz® has been marketed in the EU since 2012 and in the U.S. since 2016. The Company also markets the Belixos® dermocosmetics series in the EU, which offers specialized care for damaged or diseased skin.

Biofrontera is the first German, founder-led pharmaceutical company to obtain both EU and U.S. approval for a medical drug it has developed itself. The Biofrontera Group was established in 1997 by current CEO, Prof. Dr. Hermann Lübbert, and is listed on the Frankfurt Stock Exchange (Prime Standard).

http://www.biofrontera.com

This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.

(end)

Emitter: Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Germany
Contact Person: Investor & public relations
Phone: +49 (0) 214 87 63 20
E-Mail: press@biofrontera.com
Website: www.biofrontera.com
ISIN(s): DE0006046113 (Share)
Stock Exchange(s): Regulated Market in Dusseldorf, Frankfurt; Free Market in Berlin, Munich, Stuttgart, Tradegate
|
Top